Medical Breakthrough for treatment of Persistent Pain

What happens between injury and our perception of pain? In a groundbreaking book titled:The Biochemical origin of Pain: How a new law and new drugs have led to a breakthrough in the treatment of Persistent Pain, pain specialist Dr Sota Omoigui from the L.A. Pain Clinic in Hawthorne, California proposes the first unifying law of Pain that explains the origin of all types of pain: from Arthritis to Fibromyalgia and from Migraine to Sciatica. Dr Sota Omoigui reveals the most dramatic advance in the treatment of pain in this century. Utilizing new biotech drugs such as Enbrel or Kineret and old rediscovered drugs such as Thalidomide, painful conditions from arthritic knee joints, shoulder bursitis, herniated disks to intractable pain syndromes such as RSD/CRPS have shown dramatic improvement within minutes to days.

(PRWEB) September 4, 2002

PRESS RELEASE - Medical Breakthrough for treatment of Persistent Pain

L.A. Pain Clinic - Hawthorne, California, - September, 2002 -http://www.medicinehouse.com

What happens between injury and our perception of pain? In a groundbreaking book, pain specialist Dr Sota Omoigui from the L.A. Pain Clinic in Hawthorne, California proposes the first unifying law of Pain that explains the origin of all types of pain: from Arthritis to Fibromyalgia and from Migraine to Sciatica.

Sota Omoigui's Law of Pain states that: The origin of all pain is inflammation and the inflammatory response. The newly released book is titled: The Biochemical origin of Pain: How a new law and new drugs have led to a breakthrough in the treatment of Persistent Pain.

The entire content of the book is accessible at website http://www.medicinehouse.com. Click on BREAKING NEWS. Citing 137 literature references complimented by case reports from the L.A. Pain Clinic (Ph: 310 675-9121), Dr Sota Omoigui reveals the most dramatic advance in the treatment of pain in this century. Utilizing new biotech drugs such as Enbrel or Kineret and old rediscovered drugs such as Thalidomide, painful conditions from arthritic knee joints, shoulder bursitis, herniated disks to intractable pain syndromes such as RSD/CRPS have shown dramatic improvement within minutes to days. Dramatic results using Enbrel for herniated disks have been advertised by a clinic called DiskCureÔ in Los Angeles. According to the L.A. Times article of May 13th 2002 titled: 'Miracle Cure' for Back Pain Has Lots of Appeal--and Skeptics, the clinic charges about $2200.00 per consultation and treatment and has been criticized for secrecy and failing to provide information to other doctors and patients about the drug they use (the L.A. Times article of May 13th 2002 may be retrieved by a search of the archives at http://www.latimes.com or in http://www.medicinehouse.com/Diskcure.htm (permission pending). There can be no progress in Medicine or Science if knowledge is kept secret. Research in this field has been documented in the literature for several years. Clinical trials by some biotech companies have been recently initiated to investigate the use of the new biotech drugs and old rediscovered drugs such as Thalidomide to treat specific painful conditions. Dr Sota Omoigui is available to the press for radio and TV interviews to explain his new unifying Law of Pain and how the new biotech drugs can be used not just for herniated disks but to treat every type of pain. The new biotech drugs such as Enbrel and Kineret are approved by the FDA for the treatment of rheumatoid arthritis. They act by blocking the effect of inflammatory mediators Tumor Necrosis Factor Alpha and Interleukin -1 beta that are produced in the hot swollen joints. In his unifying Law of Pain and as explained in his new book, these inflammatory mediators as well as others whose importance have just been recognized in the last 10 years are the origin of all pain. Except for prostaglandins, which are blocked by the steroids and well know anti-inflammatory drugs such as Motrin or Celebrex, these inflammatory mediators can only be blocked by the new biotech drugs as well as a few old drugs such as Thalidomide. According to Sota Omoigui's Law of Pain, irrespective of the type of pain whether it is acute pain as in a sprain, sports injury or eurochange jellyfish sting or whether it is chronic pain as in arthritis, migraine, back or neck pain from herniated disks, RSD/CRPS pain, Fibromyalgia, Interstitial cystitis, Neuropathic pain, Post-stroke pain etc., the underlying origin is inflammation and the inflammatory response. Irrespective of the characteristic of the pain, whether it is sharp, dull, aching, burning, stabbing, numbing or tingling, all pain arise from inflammation and the inflammatory response.

Utilizing the latest biotechnology drugs, we can now treat by a simple injection under the skin that takes a few seconds, medical conditions such as rotator cuff bursitis that previously required joint injections: osteoarthritis of the knee joints that previously required arthroscopic surgery now proven to be no better than placebo: herniated disks that previously required surgery; fibromyalgia that previously had no treatment other than a referral to the psychiatrist. Dr Sota Omoigui states that the origins of pain are the biochemical mediators of inflammation and the inflammatory response.

The newly released book titled: The Biochemical origin of Pain: How a new law and new drugs have led to a breakthrough in the treatment of Persistent Pain is soon available at major book distributors, Amazon.com or by calling the publisher State -of-the-Art Technologies, Inc. at 310 675-9121.

Dr Sota Omoigui is available for radio or TV press conferences. Please call 310 675-9121 to schedule an interview.

Case Report from the L.A. Pain Clinic - Mr. C.N presented with complaints of severe pain in his right shoulder after falling on the shoulder from a height of about three feet. His pain was constant and severe, with associated difficulty abducting the joint. Patient had been seen by an orthopedic surgeon who had ordered an MRI of the left shoulder. The MRI revealed a complete rotator cuff tear involving the anterior aspect of the supraspinatus tendon adjacent to the intertuberous sulcus. The patient was advised to get immediate surgical repair of his rotator cuff. When the patient presented in our clinic he was in a lot of pain. Examination revealed severe tenderness to palpation of the left rotator cuff. His range of motion examination showed a severe limitation of abduction at 20 / 180 degrees. Mr. C.N. was placed on Tolectin DS 400 mg PO three times daily with meal and Oxycodone 5 mg 1-2 tabs PO q 4hr. He had only a slight improvement on the medications. He was subsequently given Kineret 100 mg subcutaneously. Within two minutes of administration of the Kineret, patient was able to fully raise his left shoulder to 180 / 180 degrees and was quite surprised. On reevaluation one week later, he gave the information that his pain dropped from a score of 9/10 to 3/10 within five minutes of receiving the Kineret injection. The duration of pain relief lasted for one month. He was given a second injection of Kineret 100 mg SC that has given sustained pain relief for five months till the time of publication. As at the time of this Press release, Mr. C.N has been able to avoid surgery.

ABOUT DR SOTA OMOIGUI

Sota Omoigui, MD, Medical Director of the L.A. Pain Clinic in Hawthorne, California. He is a Diplomate of The American Board of Anesthesiology with subspecialty certification in Pain Management and a Diplomate of the American Board of Pain Medicine. Dr. Sota Omoigui is author of Sota Omoigui's Anesthesia Drug Handbook (Blackwell Scientific Publishers, 1999), Sota Omoigui's Pain Drug Handbook (Blackwell Scientific Publishers, 1999) The Anesthesia Drug Handbook (Mosby Yearbook Publishers, 1995), The Pain Drug Handbook (Mosby Yearbook Publishers, 1996), Pain Relief - The L.A. Pain Clinic Guide (State-of-the-Art Technologies, 1998), The Universal Drug Infusion Ruler (State-of-the-Art Technologies, 1995) It's a Jungle out there - 163 Business Lessons from the Animal Kingdom (State-of-the-Art Technologies, 2001) and co-author of The Nigerian National Anthem (1978). Dr Sota Omoigui's drug handbooks are used worldwide and have been published in five other languages (Italian, Japanese, Malaysian, Polish and Portuguese). Dr Sota Omoigui's research focus is on the biochemical basis of Pain, and development of novel uses for old and new drugs and development of minimally invasive techniques for neural and neuromuscular blockade and relief of chronic pain. Dr Sota Omoigui pioneered the technique of audio-capnometry and holds a United States patent for the audio-capnometer monitor and a patent for the process of continuous non-invasive hemometry (measurement of hemoglobin).

On April 11th, 2002, Dr Sota Omoigui published his Law of Pain which states: - The origin of all pain is inflammation and the inflammatory response. This is the most significant advance in our understanding of Pain since the 1965 publication of the Gate Theory of Pain by Ronald Melzack and Patrick Wall.

The entire content of the book is accessible at website http://www.medicinehouse.com. Click on BREAKING NEWS. Please contact Sota Omoigui, MD 310 675-9121 regarding any questions or for an interview.

MEDICAL LITERATURE REFERENCES:

Science 1965 Nov 19;150(699):971-9

Pain mechanisms: a new theory.

Melzack R, Wall PD.

[1]

J Bone Joint Surg Am 1990 Mar;72(3):403-8

Abnormal magnetic-resonance scans of the lumbar spine in asymptomatic subjects. A prospective investigation.

Boden SD, Davis DO, Dina TS, Patronas NJ, Wiesel SW.

[2]

N Engl J Med 1994 Jul 14;331(2):69-73

Magnetic resonance imaging of the lumbar spine in people without back pain.

Jensen MC, Brant-Zawadzki MN, Obuchowski N, Modic MT, Malkasian D, Ross JS.

[3] Natural history of individuals with asymptomatic disc abnormalities in magnetic resonance imaging: predictors of low back pain-related medical consultation and work incapacity.

Boos N, Semmer N, Elfering A, Schade V, Gal I, Zanetti M, Kissling R, Buchegger N, Hodler J, Main CJ.

Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis

Raphaela Goldbach-Mansky1, Jennifer M Lee1, Joseph M Hoxworth1, David Smith II1, Paul Duray1, Ralph H Schumacher Jr1, Cheryl H Yarboro1, John Klippel1, David Kleiner1 and Hani S El-Gabalawy1

-Arthritis Res 2000 2: 145-153

[45]

Mol Cell Biol 1989 May;9(5):2239-43

Effects of botulinum toxin type D on secretion of tumor necrosis factor from human monocytes.

Imamura K, Spriggs D, Ohno T, Kufe D.

[46]

Lab Invest 2001 Aug;81(8):1109-17

Inhibitors of Phosphodiesterase Isoforms III or IV Suppress Islet-Cell Nitric Oxide Production.

Beshay E, Prud'homme GJ.

[47]

Spine 2001 Apr 15;26(8):870-5

Prevention of compartment syndrome in dorsal root ganglia caused by exposure to nucleus pulposus.

Yabuki S, Onda A, Kikuchi S, Myers RR.

[49] Amin A R, Attur M G, Thakker G D, Patel P D, Vyas P R, Patel R N, Patel I R, Abramson S B, A novel mechanism of action of tetracyclines: effects on nitric oxide syntheses, Proc Natl Acad Sci U S A 1996; 93: 14014-9.

[50] Steinrneyer J, Daufeldt S, Taiwo Y O, Pharmacological effect of tetracyclines on proteoglycanases from interleukin-l-treated articular cartilage, Biochem Pharmacol 1998; 55: 93-100

[51] Kloppenburg M, Verweij C L, Miltenburg A M, Verboeven A J, Daha M R, Dijlanans B A, Breeveld F C, The influence of tetracyclines on T cell activation, Clin EU Immunol 1995; 102: 635-41.

[52] Shapira L, Houri Y, Barak V, Soskolne W A, Halabi A, Stabholz A, Tetracycline inhibits' Porphyromonas gingivalis lipopolysaccharide- induced lesions in vivo and TNF .alpha. processing in vitro, J Periodontal Res 1997; 32: 183-8

[53] Chao C C, Hu S, Ehrlich L, Peterson P K, Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors, Brain Behav Immun 1995; 9: 355-65

[54] Bluthe R M, Dantzer R, Kelley K W, Interleukin-I mediates behavioural but not metabolic effects of tumor necrosis factor alpha in mice, Eur J Pharmacol 1991; 209: 281-3.

[55] . Hartung B P, Jung S, Stoll G, Zielasek J, Schmidt B, Archelos J J, Toyka K V, Inflammatory mediators in demyelinating disorders of the CNS and PNS, J Neuroinununol 1992; 40: 197-210.

[56] Sommer C, Schmidt C, George A, Toyka K V, A metalloprotease-inhibitor reduces pain associated behaviour in mice with experimental neuropathy, Neurosci Lett 1997;237:45-8

.

[57] Stoll G, Jung S, Jander S, van der Meide P, Hartung B P, Tumor necrosis factor-alpha in immunomediated demyelination and Wallerian degeneration of the rat peripheral nervous system, Neuroimmunol 1993; 45: 175-82.

[71]

Psychoneuroendocrinology 2000 Nov;25(8):785-97

The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice.

Kubera M, Holan V, Mathison R, Maes M.

[73]

Neuroscience 1999;91(1):211-9

Corticosterone and phenytoin reduce neuronal nitric oxide synthase messenger RNA expression in rat hippocampus.

Reagan LP, McKittrick CR, McEwen BS.

[74]

Res Commun Mol Pathol Pharmacol 1999;105(1-2):23-33

Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus.

Noda Y, Mori A, Packer L.

[4]

: Br J Anaesth 1995 Aug;75(2):125-31

Inflammatory mediators of pain.

Dray A.

[5]

Clin J Pain 1991;7 Suppl 1:S8-15

Pathophysiological mechanisms of fibromyalgia.

Zimmermann M.

[6]

Nature 410, 471 - 475 (2001) © Macmillan Publishers Ltd.

Interleukin-1-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity

Tarek A. Samad, Kimberly A. Moore, Adam Sapirstein, Sara Billet, Andrew Allchorne, Stephen Poole, Joseph V. Bonventre & Clifford J. Woolf

Eur J Neurosci 1999 Mar;11(3):837-46

Adrenergic innervation of rat sensory ganglia following proximal or distal painful sciatic neuropathy: distinct mechanisms revealed by anti-NGF treatment.

Ramer MS, Bisby MA.

[7] Hyperalgesia from subcutaneous cytokines

By Stephen Poole, Fernando de Queiroz Cunha and Sergio Henriques Ferreira

Summary

J Exp Med. 2000;191:313-320.

Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist -deficient mice.

Adv Immunol. 1993;54:167-227.

Arend WP. Interleukin-1 receptor antagonist.

J Rheumatol. 1995;22:2250-2258. van Lent PLEM, van de Loo FAJ, Holthuysen AEM, van den Bersselaar LAM, Vermeer H, van den Berg WB. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice.

J Exp Med. 2000;191:313-320

Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist -deficient mice.

Arthritis Rheum. 2000;43:2143-2151.

Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis.

J Rheumatol. 1995;22:2250-2258.

van Lent PLEM, van de Loo FAJ, Holthuysen AEM, van den Bersselaar LAM, Vermeer H, van den Berg WB. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice.

Brain Res 2000 Oct 6;879(1-2):216-25

Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain.

Arruda JL, Sweitzer S, Rutkowski MD, DeLeo JA.

[8] Intrathecal Methylprednisolone for Intractable Postherpetic Neuralgia

Naoki Kotani, Tetsuya Kushikata, Hiroshi Hashimoto, Futoshi Kimura, Masatoshi Muraoka, Misako Yodono, Mizue Asai, Akitomo Matsuki

J Neurotrauma 1999 Oct;16(10):851-63

Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats.

Bethea JR, Nagashima H, Acosta MC, Briceno C, Gomez F, Marcillo AE, Loor K, Green J, Dietrich WD.

Exp Neurol 2001 Mar;168(1):144-54

Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat.

Plunkett JA, Yu CG, Easton JM, Bethea JR, Yezierski RP.

[9] Kayama S, Konno S, Olmarker K, Yabuki S, Kikuchi S, Incision of the anulus fibrosis induces nerve root morphologic, vascular, and functional changes. An experimental study, Spine 1996; 21: 2539-43.

[10] Olmarker K, Rydevik B, Nordborg C, Autologous nucleus pulposus induces neurophysiologic and histologic changes in porcine cauda equina nerve roots, Spine 1993; 18: 1425-32.

[11] Olmarker K, Myers R R, Pathogenesis of sciatic pain: Role of herniated nucleus pulposus and deformation of spinal nerve root and DRG, Pain, 1998, 78: 9-105

[12] Hyperalgesic Actions of Cytokines on Peripheral Nerves

By Robert R. Myers, Rochelle Wagner and Linda Sorkin

P Borden, RA Heller: Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases

Crit Rev Eukaryot Gene Expr 1997, 7: 159-178

C He: Molecular mechanism of transcriptional activation of human gelatinase B by proximal promoter

Cancer Lett 1996, 106: 185-191

Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis

Raphaela Goldbach-Mansky1, Jennifer M Lee1, Joseph M Hoxworth1, David Smith II1, Paul Duray1, Ralph H Schumacher Jr1, Cheryl H Yarboro1, John Klippel1, David Kleiner1 and Hani S El-Gabalawy1

-Arthritis Res 2000 2: 145-153

J Neurosci 1996 Dec 15;16(24):7910-9

Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40).

Backstrom JR, Lim GP, Cullen MJ, Tokes ZA.

[13]

: Pain 2000 Feb;84(2-3):159-67

Cytokine involvement in dynorphin-induced allodynia.

Laughlin TM, Bethea JR, Yezierski RP, Wilcox GL.

Lakartidningen 1997 Nov 26;94(48):4461-6

[A breakthrough in the research on pain. Survey of the synaptic network may result in new analgesics]

Olgart L.

[20]

Rev Prat 1994 Jun 15;44(12):1569-71

[Substance P and rheumatic diseases]

[Article in French]

Menkes CJ, Renoux M.

Inflammation 1992 Dec;16(6):587-601

Effects of interleukin-1 beta and tumor necrosis factor-alpha on osteoblastic expression of osteocalcin and mineralized extracellular matrix in vitro.

Taichman RS, Hauschka PV.

Calcif Tissue Int 1993 Mar;52(3):227-33

Proliferative responses to estradiol, IL-1 alpha and TGF beta by cells expressing alkaline phosphatase in human osteoblast-like cell cultures.

Rickard DJ, Gowen M, MacDonald BR.

Arthritis Rheum 2001 Oct;44(10):2320-30

In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis.

Jovanovic DV, Fernandes JC, Martel-Pelletier J, Jolicoeur FC, Reboul P, Laufer S, Tries S, Pelletier JP.

[15]

Spine 2000 Dec 1;25(23):2975-80

2000 Volvo Award winner in basic science studies: Exogenous tumor necrosis factor-alpha mimics nucleus pulposus-induced neuropathology. Molecular, histologic, and behavioral comparisons in rats.

Igarashi T, Kikuchi S, Shubayev V, Myers RR

[16]

Spine 2001 Apr 15;26(8):863-9

Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica.

Olmarker K, Rydevik B.

[17]

Schmerz 2001 Dec;15(6):425-9

Radicular pain - recent pathophysiologic concepts and therapeutic implications.

Olmarker K.

[18]

J Orthop Res 2000 Sep;18(5):815-20

Nitric oxide as a mediator of nucleus pulposus-induced effects on spinal nerve roots.

Brisby H, Byrod G, Olmarker K, Miller VM, Aoki Y, Rydevik B.

[19]

Spine 1997 Nov 1;22(21):2484-8

The inflammatory properties of contained and noncontained lumbar disc herniation.

Nygaard OP, Mellgren SI, Osterud B.

[31]

Environ Health Perspect 1995 Jan;103(1):54-6

Neurogenic switching: a hypothesis for a mechanism for shifting the site of inflammation in allergy and chemical sensitivity.

Meggs WJ.

[32]

BioDrugs 2001;15(8):521-31

BioDrugs 2001;15(8):521-31

Neuroendocrine and immune aspects of fibromyalgia.

van West D, Maes M.

[33]

23: Arthritis Rheum 1994 Nov;37(11):1593-601

Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome.

Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F.

[34]

Pain 1988 Jan;32(1):21-6

Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis.

Vaeroy H, Helle R, Forre O, Kass E, Terenius L.

[35]

J Rheumatol Suppl 1989 Nov;19:94-7

Modulation of pain in fibromyalgia (fibrositis syndrome): cerebrospinal fluid (CSF) investigation of pain related neuropeptides with special reference to calcitonin gene related peptide (CGRP).

Vaeroy H, Sakurada T, Forre O, Kass E, Terenius L.

[36]

Z Rheumatol 1998;57 Suppl 2:63-6

Neurochemical pathogenesis of fibromyalgia.

Russell IJ.

[37]

Pain 2000 Aug;87(2):201-11

Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways.

Larson AA, Giovengo SL, Russell IJ, Michalek JE.

[38]

Rheumatology (Oxford) 2001 Jul;40(7):743-9

Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study.

Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH.

J Urol 2000 Dec;164(6):2119-25

Pentosanpolysulfate inhibits mast cell histamine secretion and intracellular calcium ion levels: an alternative explanation of its beneficial effect in interstitial cystitis.

Chiang G, Patra P, Letourneau R, Jeudy S, Boucher W, Green M, Sant GR, Theoharides TC.

Br J Urol 1995 Jun;75(6):744-50

Increased number of substance P positive nerve fibres in interstitial cystitis.

Pang X, Marchand J, Sant GR, Kream RM, Theoharides TC.

J Urol 1998 Aug;160(2):605-11

Comment in:

. J Urol 1998 Aug;160(2 ):298

High affinity binding sites for [3H] substance P in urinary bladders of cats with interstitial cystitis.

Buffington CA, Wolfe SA Jr.

J Urol 1992 Mar;147(3):587-91

Interstitial cystitis: increased sympathetic innervation and related neuropeptide synthesis.

Hohenfellner M, Nunes L, Schmidt RA, Lampel A, Thuroff JW, Tanagho EA.

J Urol 1996 Aug;156(2 Pt 1):532-5

Potentiation by bradykinin and substance P of purinergic neurotransmission in urinary bladder.

Patra PB, Westfall DP.

[39]

Urology 1999 Sep;54(3):450-3

Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille Calmette-Guerin treat interstitial cystitis by altering the immune profile in the bladder?

Peters KM, Diokno AC, Steinert BW.

Can J Neurol Sci 1999 Nov;26 Suppl 3:S12-9

Pathophysiology of migraine--new insights.

Hargreaves RJ, Shepheard SL.

Blood Vessels 1991;28(1-3):35-45

Innervation and effects of dilatory neuropeptides on cerebral vessels. New aspects.

Edvinsson L.

Microsc Res Tech 2001 May 1;53(3):167-78

Neurogenic inflammation in the context of migraine.

Williamson DJ, Hargreaves RJ.

Lakartidningen 2001 Sep 26;98(39):4176-83

[Both neurogenic and vascular causes of primary headache]

[Article in Swedish]

Edvinsson L.

Cerebrovasc Brain Metab Rev 1989 Fall;1(3):230-52

Neuropeptides in the cerebral circulation.

Uddman R, Edvinsson L.

[14] Regulation of meningeal blood flow by neuropeptides: Relevance to migraine

By K. Messlinger, M. Pawlak

Pain 2000 Dec 1;88(3):239-48

Possible role of inflammatory mediators in tactile hypersensitivity in rat models of mononeuropathy.

Cui JG, Holmin S, Mathiesen T, Meyerson BA, Linderoth B.

Eur J Neurosci 1999 Mar;11(3):837-46

Adrenergic innervation of rat sensory ganglia following proximal or distal painful sciatic neuropathy: distinct mechanisms revealed by anti-NGF treatment.

Ramer MS, Bisby MA.

Neurosci Lett 2002 Feb 22;319(3):137-40

Increases in the concentration of brain derived neurotrophic factor in the lumbar spinal dorsal horn are associated with pain behavior following chronic constriction injury in rats.

Miletic G, Miletic V.

Clin J Pain 2000 Jun;16(2 Suppl):S7-11

Neurotrophic factors and pain.

Apfel SC.

J Hand Surg [Am] 2001 Jul;26(4):635-44

Nerve growth factor inhibition prevents traumatic neuroma formation in the rat.

Kryger GS, Kryger Z, Zhang F, Shelton DL, Lineaweaver WC, Buncke HJ.

Pain 1999 Feb;79(2-3):265-74

Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction injury of the sciatic nerve.

Ro LS, Chen ST, Tang LM, Jacobs JM.

Clin J Pain 2000 Jun;16(2 Suppl):S12-20

Peripheral neuropathic pain: from mechanisms to symptoms.

Baron R.

[5]

27: Clin J Pain 1991;7 Suppl 1:S8-15

Pathophysiological mechanisms of fibromyalgia.

Zimmermann M.

Neuroreport 2001 Jul 20;12(10):2079-84

NF-kappa B decoy suppresses cytokine expression and thermal hyperalgesia in a rat neuropathic pain model.

Sakaue G, Shimaoka M, Fukuoka T, Hiroi T, Inoue T, Hashimoto N, Sakaguchi T, Sawa Y, Morishita R, Kiyono H, Noguchi K, Mashimo T.

[6]

Nature 410, 471 - 475 (2001) © Macmillan Publishers Ltd.

<>

Interleukin-1-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity

Tarek A. Samad, Kimberly A. Moore, Adam Sapirstein, Sara Billet, Andrew Allchorne, Stephen Poole, Joseph V. Bonventre & Clifford J. Woolf

Oyelese, A.A., Rizzo M.A., Waxman, S.G. and Kocsis, J.D. (1997) Differential effects of NGF and BDNF on axotomy-induced changes in GABAA receptor-mediated conductance and sodium currents in cutaneous afferent neurons. Journal of Neurophysiology, 78:31-42.

Waxman, S.G. (1999) The molecular pathophysiology of pain: abnormal expression of sodium channel genes and its contributions to hyperexcitability in primary sensory neurons. Pain. 6, S133-S140.

Black, J.A., Langworthy, K., Hinson, A.W., Dibb-Hajj, S.D., and Waxman, S.G. (1997) NGF has opposing effects on Na+ channel III and SNS gene expression in spinal sensory neurons. NeuroReport, 8: 2331-2335.

Everill, B., and Kocsis, J.D., (1999) Reduction of potassium currents in identified cutaneous afferent DRG neurons after axotomy. Journal of Neurophysiology, 82, 700-708.

[21]

Lancet 1993 Oct 23;342(8878):1012-6

Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients.

Veldman PH, Reynen HM, Arntz IE, Goris RJ.

[22]

Radiologe 1992 Oct;32(10):509-15

[Bone marrow edema in MRT]

[Article in German]

Vahlensieck M, Reiser M.

[23]

Pain 2000 Dec 1;88(3):259-66

Patterns of spread in complex regional pain syndrome, type I (reflex sympathetic dystrophy).

Maleki J, LeBel AA, Bennett GJ, Schwartzman RJ.

[24]

Unfallchirurg 1997 Feb;100(2):90-9

[Sudeck's syndrome. Was Sudeck right?]

[Article in German]

van der Laan L, Goris RJ.

[25]

Vasc Med 1998;3(3):207-14

Reflex sympathetic dystrophy: facts and hypotheses.

Kurvers HA.

[26]

Pharmacol Rev 2000 Dec;52(4):595-638

The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system.

Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES.

[27]

Neurology 2001 Dec 26;57(12):2179-84

The important role of neuropeptides in complex regional pain syndrome.

Birklein F, Schmelz M, Schifter S, Weber M.

[28]

Acta Orthop Belg 1998 Dec;64(4):448-51

Role of neuropeptides in pathogenesis of reflex sympathetic dystrophy.

Blair SJ, Chinthagada M, Hoppenstehdt D, Kijowski R, Fareed J.

[29] Hyperalgesia from subcutaneous cytokines

By Stephen Poole, Fernando de Queiroz Cunha and Sergio Henriques Ferreira

Rheumatology (Oxford) 2001 Sep;40(9):995-1001

Interleukin-1-induced subacromial synovitis and shoulder pain in rotator cuff diseases.

Gotoh M, Hamada K, Yamakawa H, Yanagisawa K, Nakamura M, Yamazaki H, Ueyama Y, Tamaoki N, Inoue A, Fukuda H

J Orthop Res 1999 May;17(3):392-7

Increased interleukin-1beta production in the synovium of glenohumeral joints with anterior instability.

Gotoh M, Hamada K, Yamakawa H, Nakamura M, Yamazaki H, Inoue A, Fukuda H.

Kobe J Med Sci 2001 Feb;47(1):25-34

Immunolocalization of cytokines and growth factors in subacromial bursa of rotator cuff tear patients.

Sakai H, Fujita K, Sakai Y, Mizuno K.

NEJM Volume 347:81-88 July 11, 2002 Number 2

A Controlled Trial of Arthroscopic Surgery for Osteoarthritis of the Knee

J. Bruce Moseley, M.D., Kimberly O'Malley, Ph.D., Nancy J. Petersen, Ph.D., Terri J. Menke, Ph.D., Baruch A. Brody, Ph.D., David H. Kuykendall, Ph.D., John C. Hollingsworth, Dr.P.H., Carol M. Ashton, M.D., M.P.H., and Nelda P. Wray, M.D., M.P.H.